{
    "nctId": "NCT02670577",
    "briefTitle": "Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry",
    "officialTitle": "Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 481,
    "primaryOutcomeMeasure": "Change in Treatment Decision",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Eligible to receive chemotherapy and endocrine therapy as defined by a good Karnofsky index (\u226580) and no hematologic, cardiologic or hepatic contraindications, nor any impeding comorbidity\n* Informed consent form signed on the same day or before enrollment\n* \u2265 18 years of age at time of consent Per study arm\n* Histologically proven invasive stage I and II breast cancer and Hormone Receptor positive (ER+ PR-, ER- PR+ or ER+ PR+) according to local standards \\& HER2 negative: IHC 0-1+, or FISH or other ISH non-amplified (locally assessed)\n\nIMPACt study; version 1 2015 September 1 Page 10 Axillary lymph node status: 0-3 involved (macro metastases i.e. \\>2mm OR micro metastases i.e. \\>0.2-2mm)\n\nOR\n\nHistologically proven invasive T1a or T1b breast cancer \\& Hormone receptor negative (ER- and PR-) according to local standards \\& HER2 negative: IHC 0-1+, or FISH or other ISH non-amplified (locally assessed)\n\n\\& Axillary lymph node status: 0-1 involved (macro metastases i.e. \\>2mm OR micro metastases i.e. \\>0.2-2mm)\n\nOR\n\nHistologically proven invasive T1a or T1b breast cancer\n\n\\& Hormone receptor negative or positive (ER-PR-, ER+PR-, ER-PR+, ER+PR+) according to local standards\n\n\\& HER2 positive: IHC 3+, or FISH or other ISH amplified (locally assessed)\n\n\\& Axillary lymph node status: 0-1 involved (macro metastases i.e. \\>2mm OR micro metastases i.e. \\>0.2-2mm)\n\nExclusion Criteria:\n\n* Previous diagnosis of breast malignancy unless disease free for 10 years\n* Metastatic disease\n* Tumor sample shipped to Agendia with \u2264 30% tumor cells or that fails QA or QC criteria\n* Women who have started or completed adjuvant chemotherapy or neo-adjuvant chemotherapy for current breast cancer",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}